ATLANTA, May 21, 2012 /PRNewswire/ -- CryoLife,
Inc. (NYSE: CRY), a leading medical device company focused on
cardiac and vascular surgery, announced today that Jon Salveson, Vice Chairman of Investment
Banking at Piper-Jaffray & Co (NYSE: PJC), has been elected to
the Company's Board of Directors, effective May 16, 2012.
Steven G. Anderson, Chairman,
President and Chief Executive Officer of CryoLife, said, "Jon is an
expert in the medical devices industry having spent the last 19
years in healthcare investment banking and corporate finance at
Piper Jaffray. His industry knowledge and M&A experience will
be a welcome asset as we continue to pursue our corporate
development initiatives, including expanding our higher growth,
higher margin medical device segment."
Mr. Salveson joined Piper Jaffray in 1993, became a Managing
Director in 1999, and was named the Group Head of Piper Jaffray's
healthcare investment banking group in 2001. He was appointed
Global Head of Investment Banking and a member of the Executive
Committee of Piper Jaffray in 2004. He has served as Vice Chairman
of Investment Banking at Piper Jaffray since 2010. Throughout
his career at Piper Jaffray, Mr. Salveson's area of practice has
focused on the medical device industry.
Mr. Salveson started his career as a market manager at
Bio-Metrics Systems (now part of Surmodics, Inc), an innovator in
medical device surface modification, where he gained experience
working in cardiology and interventional medicine. Mr. Salveson
received his M.M.M. in finance from the Kellogg Graduate School of
Management at Northwestern University
and a B.A. in chemistry and religion from St.
Olaf College.
About CryoLife
Founded in 1984, CryoLife, Inc. is a leader in the processing
and distribution of implantable living human tissues for use in
cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve® SG pulmonary
heart valve, processed using CryoLife's proprietary SynerGraft®
technology, has FDA 510(k) clearance for the replacement of
diseased, damaged, malformed, or malfunctioning native or
prosthetic pulmonary valves. CryoLife's CryoPatch® SG
pulmonary cardiac patch has FDA 510(k) clearance for the repair or
reconstruction of the right ventricular outflow tract (RVOT), which
is a surgery commonly performed in children with congenital heart
defects, such as Tetralogy of Fallot, Truncus Arteriosus, and
Pulmonary Atresia. CryoPatch SG is distributed in three
anatomic configurations: pulmonary hemi-artery, pulmonary trunk,
and pulmonary branch. CryoLife's BioGlue® Surgical Adhesive is
FDA approved as an adjunct to sutures and staples for use in adult
patients in open surgical repair of large vessels. BioGlue is
also CE marked in the European Community and approved in
Canada and Australia for use in soft tissue repair and
was recently approved in Japan for
use in the repair of aortic dissections. CryoLife, through its
subsidiary Cardiogenesis Corporation, specializes in the treatment
of cardiovascular disease and the sale of devices that treat severe
angina. Its market leading FDA-approved Holmium: YAG laser
system and single use fiber-optic delivery systems are used to
perform a surgical procedure known as Transmyocardial
Revascularization (TMR). CryoLife distributes PerClot®, an
absorbable powder hemostat, in the European Community. CryoLife's
BioFoam™ Surgical Matrix is CE marked in the European Community for
use as an adjunct in the sealing of abdominal parenchymal tissues
(liver and spleen) when cessation of bleeding by ligature or other
conventional methods is ineffective or impractical.
For additional information about the company, visit CryoLife's
website:
http://www.cryolife.com.
CryoLife
D. Ashley
Lee
Executive
Vice President, Chief Financial Officer
and Chief
Operating Officer
Phone:
770-419-3355
|
The
Ruth Group
Nick
Laudico / Zack Kubow
646-536-7030 / 7020
nlaudico@theruthgroup.com
zkubow@theruthgroup.com
|
SOURCE CryoLife, Inc.